BYETTA is a non-insulin type 2 diabetes injection medication for adults. Important Safety Information for BYETTA (exenatide) injection . with prior severe hypersensitivity reactions to exenatide or to any of the product components. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution for injection in pre-filled pen exenatide. Read all of this leaflet carefully.

Author: Yozshukora Doucage
Country: Mongolia
Language: English (Spanish)
Genre: Music
Published (Last): 21 February 2013
Pages: 415
PDF File Size: 18.43 Mb
ePub File Size: 18.30 Mb
ISBN: 813-3-52419-817-3
Downloads: 63201
Price: Free* [*Free Regsitration Required]
Uploader: Kiran

Before taking BYETTA, tell your healthcare provider if you have had pancreatitis, stones in your gallbladder gallstones ecenatide, a history of alcoholism, or high blood triglyceride levels. No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic drug.

If pancreatitis is suspected, BYETTA should be discontinued promptly and should not be restarted if pancreatitis is confirmed. Edenatide initiation and dose increases of BYETTA, observe patients carefully for pancreatitis including persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting.

Official BYETTA® (exenatide) injection Healthcare Professional Website

Tell your healthcare provider if you have or had kidney problems or a kidney transplant. You are encouraged to report negative side effects of prescription drugs to the FDA.

BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. Symptoms of exenwtide severe allergic reaction include severe rash or itching, swelling of your face, lips, and throat that may cause difficulty breathing or swallowing, feeling faint or dizzy and very rapid heartbeat.

Type 2 Diabetes Medication | BYETTA® (exenatide) injection

Patients may develop antibodies to exenatide. The most frequently reported adverse reactions leading to withdrawal for Byetta-treated patients were nausea 5. Talk to your healthcare provider first if you are breastfeeding or plan to breastfeed. AstraZeneca is not responsible for the privacy policy of any third-party websites. Use in pediatric patients is indert recommended as safety and effectiveness have not been established.


Your risk for getting low exwnatide sugar hypoglycemia is higher if you take BYETTA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin.

Staying Active Learn how regular physical activity can help you manage type 2 diabetes. This site is intended for US Consumers.

The Double B logo is a trademark of the AstraZeneca group of companies. Postmarketing reports of increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin. AstraZeneca provides this link as a service to website visitors. These may be symptoms of pancreatitis. BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

All other trademarks are property of their packagge owners. This product information is intended for US Healthcare Professionals only. BYETTA should not be used in people with type 1 onsert or people with diabetic ketoacidosis a condition caused by very high blood sugar. All other trademarks are property of their respective owners. Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic ihsert necrotizing pancreatitis.

Tell your healthcare provider if you are pregnant or plan to become pregnant. To report drug exposure during pregnancy call If worsening ezenatide or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy. No placebo-treated patients withdrew due to nausea or vomiting. Write your html here It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using Paclage consider other antidiabetic therapies for these patients.

Use with caution in patients with renal transplantation or when initiating or escalating the dose in patients with moderate renal failure.

Welcome to BYETTA.com!

Because exenatide is commonly associated with gastrointestinal adverse reactions, BYETTA is not recommended in patients with severe gastrointestinal disease eg gastroparesis. BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with pakage and exercise.


Stop taking BYETTA and call your healthcare provider right away if you have pain in your stomach area abdomen that is severe, and will not go away, occurs with or without vomiting or is felt going from your abdomen through to your back. Postmarketing reports of serious hypersensitivity reactions eg anaphylaxis and angioedema.

exehatide The most common side effects with BYETTA include nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, acid stomach, constipation, and weakness. Increased risk of hypoglycemia when used in combination with a sulfonylurea SU or when used with a glucose-independent insulin exenative eg, meglitinides. Oral medications dependent on threshold concentrations for efficacy, such as contraceptives or antibiotics, should be taken at least 1 hour before BYETTA.

BYETTA slows gastric emptying and can reduce the extent and rate of absorption of orally administered drugs. Go to Healthcare Professional Site. Approved Uses BYETTA is an injectable prescription medicine that may improve blood sugar glucose control exenattide adults with type 2 diabetes, when used with diet and exercise.

Based on animal data, BYETTA may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When used with insulin, evaluate and consider reducing the insulin dose in patients at increased risk of hypoglycemia.

Add BYETTA to insulin glargine as a complementary action to help improve glycemic control

Use with caution with medications that have a narrow therapeutic index or require rapid gastrointestinal absorption. Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed.

Go to Patient Site.